When a new cancer drug shows promise, it trends globally. When a gene therapy corrects a rare mutation, headlines follow. But when a novel antibiotic advances against drug-resistant pathogens — silence.
That silence is dangerous.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
